drugset / Trial / NCT03371459

Assessment of the Safety, Efficacy, PK, and Extrapulmonary Pharmacodynamics (PD) of Albuterol Sulfate Pressurized Inhalation Suspension (Hereafter Referred to as AS MDI) Compared to Proventil as an Active Control in Subjects With Asthma

NCT03371459

Phase 2 Completed 46 enrolled AstraZeneca
RandomizedCrossoverOpen-labelTreatment

Summary

This is a randomized, cumulative dose, open-label, 2-period crossover, multi-center study to assess the safety, efficacy, PK, and extrapulmonary PD of cumulative doses of AS MDI compared to cumulative doses of Proventil as an active control in subjects with mild to moderate asthma

Timeline

Start
2017-12-29
Primary completion
2018-03-26
Completion
2018-03-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Salbutamol Unknown 90 ug Inhaled

Indications